Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months

Vaccine

Volumn 29, Issue 37, 2011, Pages 6408-6418

  Risi, George ^a   Frenette, Louise ^b   Langley, Joanne M ^c   Li, Ping ^d   Riff, Dennis ^e   Sheldon, Eric ^f   Vaughn, David W ^d   Fries, Louis ^d  

^a Infectious Disease Specialists   (United States)

^b QT Research   (Canada)

^c IWK HEALTH CENTRE   (Canada)

^d GLAXOSMITHKLINE   (United States)

^e Clinical Research Institute   (United States)

^f MIAMI RESEARCH ASSOCIATES   (United States)

Author keywords

AS03 Adjuvant System; H5N1 subtype; Influenza A virus; Influenza vaccines

Indexed keywords

ADJUVANT; ANTIBODY; AS03 ADJUVANT; HEMAGGLUTININ; HEMAGGLUTININ ANTIGEN; INFLUENZA VACCINE; OIL; TOCOPHEROL; UNCLASSIFIED DRUG; VIRUS ANTIGEN; WATER;

ADULT; ANTIBODY TITER; ARTHRITIS; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; EMULSION; FATIGUE; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL PROCEDURES; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; INJECTION SITE SWELLING; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OROPHARYNGEAL PAIN; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINUSITIS; SKIN REDNESS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION;

EID: 80051556779     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.072     Document Type: Article

References (27)

1. WHO Pandemic influenza preparedness and response: a WHO guidance document 2009, Available from: http://www.who.int/csr/disease/influenza/PIPGuidance09.pdf [cited 2010 June 30].
2. WHO. H5N1 avian influenza: timeline of major events [updated 2010 March 16; cited 2010 June 30]. Available from: http://www.who.int/csr/disease/avian_influenza/2010_03_16_h5n1_avian_influenza_timeline.pdf.
3. Melidou A., Gioula G., Exindari M., Chatzidimitriou D., Diza-Mataftsi E. Influenza A(H5N1): an overview of the current situation. Euro Surveill 2009, 14:312-315.
4. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
5. WHO Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use in human vaccines 2009, Available from: http://www.who.int/csr/disease/avian_influenza/guidelines/200902_H5VaccineVirusUpdate.pdf [cited 2010 June 30].
6. Leroux-Roels I., Roman F., Forgus S., Maes C., De Boever F., Dramé M., et al. Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28:849-857.
7. WHO Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines 2007, March, Available from: http://www.who.int/csr/disease/avian_influenza/guidelines/summaryH520070403.pdf [cited 2010 August 24].
8. Leroux-Roels I., Bernhard R., Gerard P., Drame M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3:e1665.
9. Jennings L.C., Monto A.S., Chan P.K., Szucs T.D., Nicholson K.G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008, 8:650-658.
10. Nichol K.L., Treanor J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006, 194(Suppl. 2):S111-S118.
11. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K.B., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197:667-675.
12. Osterhaus Albert Pre- or post-pandemic influenza vaccine? Editorial. Vaccine 2007, 25:4983-4984.
13. Schwarz T.F., Horacek T., Knuf M., Dammann H.G., Roman F., Dramé M., et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomised trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009, 27:6284-6290.
14. Stephenson I., Nicholson K.G., Hoschler K., Zambon M.C., Hancock K., DeVos J., et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008, 395:1631-1633.
15. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008, 198:642-649.
16. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005, 191:1210-1215.
17. GlaxoSmithKline. First pre-pandemic vaccine approved to help protect against pandemic influenza: GSK's Prepandrix™ obtains first EU authorisation for pre-pandemic H5N1 vaccine [cited 2010 July 15]. Available from: http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10048.htm.
18. Carter N.J., Plosker G.L. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix™]: a review of its use as an active immunization against influenza A subtype H5N1 virus. Biodrugs 2008, 22:279-292.
19. Langley J.M., Frenette L., Ferguson L., Riff D., Sheldon E., Risi G., et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomised controlled phase 1/2 trial in adults. J Infect Dis 2010, 201:1644-1653.
20. US Food and Drug Administration. Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines [updated 2007 May; cited 2010 June 30]. Available from: http://www.fda.gov/cber/gdlns/panfluvac.htm.
21. Hehme N., Engelmann H., Kuenzel W., Neumeier E., Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004, 103:163-171.
22. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004, 103:91-95.
23. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
24. Reed L., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
25. Newcombe R.G. Interval estimation for the difference between independent proportions: comparison of eleven methods (method 5). Stat Med 1998, 17:873-890.
26. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367:1657-1664.
27. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.